A study demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication
A study featured in the European Journal of Ophthalmology has demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication.
Dr Gil Calvão-Santos et al., Ophthalmology Department, Centro Hospitalar de Entre o Duoro e Vouga-Unidade de Santa Maria da Feira, Portugal, split 27 patients with dry eye symptoms into 4 groups. Group A was administered Tears Again, B was given Optive, C received Opticol and D was the control group.
Patients were observed on day 0, 7 and 30 after being administered the AT. Data analysis was conducted, as well as tear break-up time (TBUT), Schirmer tests and Ocular Surface Disease Index.
The findings demonstrated no significant differences between any of the groups. From day 0 to 30 the amount of eyes with abnormal TBUT was reduced. However, eyes presenting with an average TBUT increased in all groups and Schirmer value decreased in groups B, C and D, but increased in group A.
Tear film was recovered in all of the AT groups, but AT targeting just the internal and intermediate layer caused a small decline on lachrymal production. It was suggested that different types of AT should be used on different layers of the eye for the treatment of corneal surface diseases affecting eye lubrication.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.